Cargando…
Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
Autores principales: | van Kleef, Laurens A., de Knegt, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426377/ https://www.ncbi.nlm.nih.gov/pubmed/35593157 http://dx.doi.org/10.1002/hep4.2006 |
Ejemplares similares
-
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: Takahashi, Hirokazu, et al.
Publicado: (2022) -
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021) -
Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
por: van Kleef, Laurens A., et al.
Publicado: (2023) -
Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014) -
Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study
por: van Kleef, Laurens A., et al.
Publicado: (2021)